Polyrizon Ltd. (PLRZ) Stock Price, Quote & News

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is he...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 374 0120

Website: www.polyrizon-biotech.com

Address:

5 HaPnina Street, Ra'anana, Israel

TheDragonsClaw Jun. 3 at 10:05 PM

$BLMZ $PLRZ $BTCT.X $BTOG Crtypto

0 · Reply

TheDragonsClaw Jun. 3 at 8:15 PM

$BLMZ $PLRZ )px

0 · Reply

patrick1956 Jun. 2 at 11:16 PM

$PLRZ... this will bleed until the FDA APPROVE their drug..this should be in the next short while...good time to accumulate ...imo

1 · Reply

Tbirdyguy Jun. 1 at 7:58 PM

$PLRZ back to bleeding

0 · Reply

Tbirdyguy May. 26 at 1:02 PM

$PLRZ where's the fucking news!?!?! Did pl16 just fucking die? They have a site for pl14, get the trials going

0 · Reply

Smallsmall May. 24 at 11:38 AM

$PLRZ let’s get this over $20 during PM Tuesday!

1 · Reply

AdrianCartier May. 23 at 10:34 PM

$PLRZ 💎

0 · Reply

uptrend2025 May. 22 at 2:35 PM

$PLRZ Interesting

0 · Reply

BillionaireMotion May. 21 at 8:52 PM

Make sure to keep EZRA on your watchlist ! Taking a position at these levels. Looking for a massive run. EZRA has barely 500k shares outstanding. Which makes it squeezable! They had great news this week, Would not be surprised if it runs wild soon. So many low floats are squeezing 300%+ lately.. The key is to add before the crowd New plays this week: $BLMZ $PLRZ $BTCT.X $BTOG

0 · Reply

Vale84 May. 19 at 12:08 PM

$PLRZ RSI under 50 = momentum still weak

1 · Reply

Polyrizon signs clinical trial agreement with clinical research site for Nasarix

May 13, 2026, 9:25 AM EDT - 22 days ago

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

May 11, 2026, 7:25 AM EDT - 24 days ago

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

2026-05-04T13:47:12.000Z - 4 weeks ago

Polyrizon amends patent application claims for intranasal drug delivery platform

May 4, 2026, 8:45 AM EDT - 4 weeks ago

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

2026-04-28T14:31:03.000Z - 5 weeks ago

Polyrizon Ltd trading halted, volatility trading pause

2026-04-28T14:25:09.000Z - 5 weeks ago

Polyrizon Ltd trading resumes

2026-04-27T13:57:32.000Z - 5 weeks ago

Polyrizon files European patent application for Trap & Target platform

Apr 27, 2026, 9:28 AM EDT - 5 weeks ago

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

2026-04-23T23:30:28.000Z - 6 weeks ago

Polyrizon files to sell 0.5M shares of common stock for holders

Apr 8, 2026, 4:16 PM EDT - 2 months ago

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Mar 26, 2026, 9:23 AM EDT - 2 months ago

Polyrizon Provides 2025 and Recent Highlights

Mar 25, 2026, 5:25 PM EDT - 2 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

2026-03-24T13:05:32.000Z - 2 months ago

Polyrizon to acquire 20% stake in Colugo for up to $6M

Mar 24, 2026, 8:47 AM EDT - 2 months ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

2026-03-17T15:51:34.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-17T12:35:48.000Z - 2 months ago

Polyrizon signs agreement with research organization for clinical development

Mar 17, 2026, 8:25 AM EDT - 2 months ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

2026-03-10T12:09:52.000Z - 3 months ago

Polyrizon announces production of GMP batch of Clinical Trial Material

Mar 10, 2026, 7:55 AM EDT - 3 months ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

2026-02-26T13:40:23.000Z - 3 months ago

Polyrizon announces results from study evaluating profile of naloxone formula

Feb 26, 2026, 8:12 AM EST - 3 months ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 17, 2026, 11:32 AM EST - 3 months ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

2026-02-10T12:10:14.000Z - 4 months ago

Polyrizon intends to acquire a 51% stake in Arrow Aviation

Feb 10, 2026, 6:55 AM EST - 4 months ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

2026-02-06T13:01:07.000Z - 4 months ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

CMND

2026-02-06T13:00:53.000Z - 4 months ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

CMND

Feb 6, 2026, 7:55 AM EST - 4 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

2026-02-04T16:40:13.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

2026-02-04T12:15:20.000Z - 4 months ago

Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M

Feb 4, 2026, 7:12 AM EST - 4 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

2026-01-22T14:31:23.000Z - 4 months ago

Polyrizon initiates key usability study program for NASARIX

Jan 22, 2026, 9:25 AM EST - 4 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

2026-01-13T13:55:15.000Z - 5 months ago

Polyrizon announces board authorized exploration of investment opportunities

Jan 13, 2026, 8:39 AM EST - 5 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 8, 2026, 8:45 AM EST - 5 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 5, 2026, 9:07 AM EST - 5 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 2, 2026, 8:30 AM EST - 5 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Dec 29, 2025, 7:20 AM EST - 5 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 19, 2025, 8:20 AM EST - 5 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 11, 2025, 8:15 AM EST - 6 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 8, 2025, 8:55 AM EST - 6 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 4, 2025, 7:32 AM EST - 6 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 3, 2025, 9:28 AM EST - 6 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 2, 2025, 7:55 AM EST - 6 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Nov 6, 2025, 8:55 AM EST - 7 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Oct 6, 2025, 8:21 AM EDT - 8 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Sep 19, 2025, 8:15 AM EDT - 9 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 12, 2025, 7:26 AM EDT - 9 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Aug 14, 2025, 8:14 AM EDT - 10 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Jul 15, 2025, 7:55 AM EDT - 11 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jun 12, 2025, 7:32 AM EDT - 1 year ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

May 23, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 21, 2025, 7:10 AM EDT - 1 year ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 13, 2025, 7:45 AM EDT - 1 year ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 14, 2025, 8:35 AM EDT - 1 year ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 13, 2025, 7:51 AM EDT - 1 year ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 11, 2025, 4:27 PM EDT - 1 year ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 10, 2025, 7:47 AM EDT - 1 year ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

TheDragonsClaw Jun. 3 at 10:05 PM

$BLMZ $PLRZ $BTCT.X $BTOG Crtypto

0 · Reply

TheDragonsClaw Jun. 3 at 8:15 PM

$BLMZ $PLRZ )px

0 · Reply

patrick1956 Jun. 2 at 11:16 PM

$PLRZ... this will bleed until the FDA APPROVE their drug..this should be in the next short while...good time to accumulate ...imo

1 · Reply

Tbirdyguy Jun. 1 at 7:58 PM

$PLRZ back to bleeding

0 · Reply

Tbirdyguy May. 26 at 1:02 PM

$PLRZ where's the fucking news!?!?! Did pl16 just fucking die? They have a site for pl14, get the trials going

0 · Reply

Smallsmall May. 24 at 11:38 AM

$PLRZ let’s get this over $20 during PM Tuesday!

1 · Reply

AdrianCartier May. 23 at 10:34 PM

$PLRZ 💎

0 · Reply

uptrend2025 May. 22 at 2:35 PM

$PLRZ Interesting

0 · Reply

BillionaireMotion May. 21 at 8:52 PM

0 · Reply

Vale84 May. 19 at 12:08 PM

$PLRZ RSI under 50 = momentum still weak

1 · Reply

patrick1956 May. 15 at 8:45 PM

$PLRZ ...you've to remember where this originated?...who controls this company?...where this company board is located?...all comes to the understanding that who controls USA...control the narrative...imo

1 · Reply

focafoca99 May. 13 at 2:54 PM

$PLRZ signed its first U.S. clinical trial agreement for the NASARIX allergy blocker.

0 · Reply

Stock_Catcher May. 13 at 1:25 PM

$PLRZ Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

0 · Reply

MysticMorpheus May. 8 at 6:25 PM

AMS might be the most bullish smallcap setup. On breakout watch! Make sure to keep eyes on ticker AMS.✅ AMS looking strong right now! ✅ No current dilution ✅ Volume picking up ✅ Momentum building ✅ Clean chart setup ✅ Major contract locked through 2033 ✅ Improving fundamentals $AEHL $IBRX $ILLR $PLRZ ..121

0 · Reply

Tbirdyguy May. 8 at 5:02 PM

$PLRZ looks like the market has been anticipating something big over the last 3 weeks. Solid moves today after abismal volume all week. Testing recent heights in the 17s. A pr sends this well into the 20s

0 · Reply

Shakyaasha May. 5 at 7:30 PM

$PLRZ

1 · Reply

luminouslumens May. 2 at 8:33 PM

$PLRZ $EUDA $ONEG $AKAN A few multi-day movers to keep an eye on Monday

0 · Reply

Tbirdyguy Apr. 28 at 2:33 PM

$PLRZ fucking

0 · Reply

labububub Apr. 28 at 2:13 PM

$PLRZ

0 · Reply

patrick1956 Apr. 28 at 2:29 AM

$PLRZ ...European submission fail...FDA is not accepting their submission with any success...thus the submission at European...now both fail....look for this to head back under $10. ..imo

1 · Reply

Stock_Catcher Apr. 28 at 2:11 AM

Treasure Tuesday Watchlist Pt.5 $OPEN $GNS $ASST $DVLT $PLRZ Let's Dominate Tomorrow

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,429,814
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A